AseBio
Registrarse
Registrarse
Registrarse

Capacidades de investigación y tecnológicasActualizado el 4 de mayo de 2026

Physicochemical Characterization of Nanomedicines

Communication Manager en NANBIOSIS-ICTS

Zaragoza, España

Acerca de

One of the causes that increases the time required to reach the market in nanotherapeutics is the preclinical validation. The standard protocols for more traditional drugs are not applicable for nanomedicines, starting with the study of the physicochemical properties of the nanomaterials. NANBIOSIS offers a complete study plan tailored to meet the demands of each nanomedicine product, from the properties of the materials all the way to their preclinical validation. This is developed in collaboration with the user and starting from a set of basic analytical tests to more sophisticated experiments. Also, some of them are available under GLP for regulatory purposes.

Description

We offer a complete Physicochemical Characterization. e.g., size distribution, composition, purity, surface characteristics, stability, and more adapted to the different products by using the most sophisticated equipment and taking advantage of the expertise of scientist internationally recognized in the matter. 

More info: https://www.nanbiosis.es/physicochemical-characterization-of-nanomedicines/

Tipo

  • Enfermedades infecciosas
  • Sistema nervioso central
  • Detección de sustancias
  • Enzimas

Organización

NANBIOSIS-ICTS

Valencia, España

Oportunidades similares

  • Capacidades de investigación y tecnológicas

    In vitro Characterization of Nanomedicines

    • Inmunología
    • Enfermedades infecciosas

    Gabriel Alfranca

    Communication Manager en NANBIOSIS-ICTS

    Zaragoza, España

  • Capacidades de investigación y tecnológicas

    In vivo Characterization of Nanomedicines

    • Oncología
    • Inmunología
    • Enfermedades infecciosas
    • Sistema digestivo y hepatología
    • Enfermedades cardiovasculares y sistema circulatorio

    Gabriel Alfranca

    Communication Manager en NANBIOSIS-ICTS

    Zaragoza, España

  • Capacidades de investigación y tecnológicas

    Biofunctionalized Nanoconjugates: Design, Production, and Characterization

    • Detección de sustancias
    • Sistema nervioso central
    • Sangre y sistema linfático
    • Enfermedades cardiovasculares y sistema circulatorio

    Gabriel Alfranca

    Communication Manager en NANBIOSIS-ICTS

    Zaragoza, España